🟢 Ideaya Biosciences Inc is trading 5.8% up today after Phase 1 trial enrollment for MTAP-deleted tumors

Ideaya Biosciences Inc is trading 5.8% up at $31.98 in pre-market, extending the strong momentum seen in the previous session.

• The stock continues to climb following the announcement of the first patient enrolled in a Phase 1 trial evaluating the combination of IDE892 and IDE397 for MTAP-deleted solid tumors.
• The clinical study targets high-need indications including non-small cell lung and pancreatic cancers, serving as a significant catalyst for the company's oncology pipeline.
• Shares are showing relative strength and outperforming the broader market, which remains largely flat in early trading.